Jung Min Bae1, June Hyunkyung Lee2, Jae Seung Yun3, Byeol Han2, Tae Young Han4. 1. Department of Dermatology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea. 2. Department of Dermatology, College of Medicine, Nowon Eulji Medical Center, Eulji University, Seoul, Korea. 3. Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea. 4. Department of Dermatology, College of Medicine, Nowon Eulji Medical Center, Eulji University, Seoul, Korea. Electronic address: dermahan@gmail.com.
Abstract
BACKGROUND: Associations between vitiligo and thyroid diseases have been reported repeatedly. OBJECTIVE: We investigated the associations between vitiligo and overt autoimmune thyroid diseases and thyroid cancer using the Korean National Health Insurance claims database. METHODS: We defined patients with vitiligo as those whose records showed ≥4 physician contacts between 2009 and 2013 in which vitiligo was the principal diagnosis. We also established an age- and sex-matched control group without vitiligo (2 per 1 vitiligo patient). The outcomes of interest were concurrent Graves disease and Hashimoto thyroiditis (the patients were taking relevant thyroid medications) and thyroid cancer. RESULTS: The study enrolled 73,336 vitiligo patients and 146,672 controls. Patients with vitiligo were at increased risks of Graves disease (odds ratio [OR] 2.610 [95% confidence interval {CI} 2.319-02.938]), Hashimoto thyroiditis (OR 1.609 [95% CI 1.437-1.802]), and thyroid cancer (OR 1.127 [95% CI 1.022-1.242]), compared with the controls. The associations were consistently stronger in males and younger patients. LIMITATIONS: Individual clinical information was not available, and the homogeneous population may limit the generalizability of the results. CONCLUSION: Vitiligo was significantly associated with overt autoimmune thyroid diseases and overt thyroid cancer.
BACKGROUND: Associations between vitiligo and thyroid diseases have been reported repeatedly. OBJECTIVE: We investigated the associations between vitiligo and overt autoimmune thyroid diseases and thyroid cancer using the Korean National Health Insurance claims database. METHODS: We defined patients with vitiligo as those whose records showed ≥4 physician contacts between 2009 and 2013 in which vitiligo was the principal diagnosis. We also established an age- and sex-matched control group without vitiligo (2 per 1 vitiligo patient). The outcomes of interest were concurrent Graves disease and Hashimoto thyroiditis (the patients were taking relevant thyroid medications) and thyroid cancer. RESULTS: The study enrolled 73,336 vitiligo patients and 146,672 controls. Patients with vitiligo were at increased risks of Graves disease (odds ratio [OR] 2.610 [95% confidence interval {CI} 2.319-02.938]), Hashimoto thyroiditis (OR 1.609 [95% CI 1.437-1.802]), and thyroid cancer (OR 1.127 [95% CI 1.022-1.242]), compared with the controls. The associations were consistently stronger in males and younger patients. LIMITATIONS: Individual clinical information was not available, and the homogeneous population may limit the generalizability of the results. CONCLUSION: Vitiligo was significantly associated with overt autoimmune thyroid diseases and overt thyroid cancer.